Search

Zentalis Pharmaceuticals Inc

Fermé

2.76 -4.83

Résumé

Variation du prix de l'action

24h

Actuel

Min

2.77

Max

3.06

Chiffres clés

By Trading Economics

Revenu

-42M

-78M

BPA

-0.59

Employés

106

EBITDA

-42M

-77M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+185.71% upside

Dividendes

By Acuity

Prochains Résultats

6 nov. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-44M

287M

Ouverture précédente

7.59

Clôture précédente

2.76

Zentalis Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

23 sept. 2026, 23:56 UTC

In after-market trading, Interactive Brokers Group Inc is roughly flat, with price fluctuations reflecting minimal movement since Wednesday's close.

23 sept. 2026, 23:56 UTC

Correlated Moves

Allegiant Travel Co is trading modestly higher in after-market hours, recovering from earlier losses and currently positioned in the middle of its one-month trading range.

23 sept. 2026, 23:56 UTC

Arrowhead Pharmaceuticals Inc saw a modest decline in after-market trading, remaining significantly below its 20-day moving average and near the lower end of its one-month range.

23 sept. 2026, 23:56 UTC

Dow Inc saw a slight decline in after-market trading, remaining below its 20-day moving average and near the lower end of its one-month range.

23 sept. 2026, 23:55 UTC

Rush Street Interactive Inc. is trading roughly flat during after-market hours, following eight consecutive sessions with lower closes and remaining below its 20-day moving average.

23 sept. 2026, 23:55 UTC

Endava PLC is seeing a slight decline in after-market trading, continuing a trend of lower daily closes and trading below its 20-day moving average.

23 sept. 2026, 23:55 UTC

Delek US Holdings Inc is trading modestly higher during after-market hours, recovering from earlier declines while remaining below its 20-day moving average.

23 sept. 2026, 23:55 UTC

Macro News

The U.S. Dollar Index is trading roughly flat, with macroeconomic developments highlighting oil supply from the Strait of Hormuz amid rising U.S. crude inventories.

23 sept. 2026, 23:55 UTC

Cardinal Health Inc is trading modestly higher in after-market hours following slight fluctuations during the session, remaining below its 20-day moving average.

23 sept. 2026, 23:52 UTC

Northrop Grumman Corp is declining in after-market trading, settling lower after briefly turning positive and remaining below its 20-day moving average.

23 sept. 2026, 23:52 UTC

South Africa's Balance of Trade Data Release on September 30: Market Eyes Sustained Surplus Amid Mixed Economic Signals.

23 sept. 2026, 23:52 UTC

Germany's Inflation Rate Expected to Remain Stable Ahead of September 30 Release Amid Geopolitical Tensions and Strong Manufacturing Activity

23 sept. 2026, 23:52 UTC

Germany's Inflation Rate Release on September 30 Expected to Show Stability Amid Strong Manufacturing Growth and Geopolitical Tensions.

23 sept. 2026, 23:52 UTC

Mixed Sentiment Ahead of U.S. New Home Sales Data Release Amidst Slowing Activity and Luxury Market Resilience

23 sept. 2026, 23:52 UTC

New Home Sales Expected at 0.62 Million Amid Rising Prices and Cautious Market Sentiment

23 sept. 2026, 23:52 UTC

Japan's Tankan Large Manufacturers Index set for release on September 30, amid mixed market sentiments influenced by global economic factors and rising interest rate concerns.

23 sept. 2026, 23:51 UTC

Cleveland-Cliffs Inc has traded lower in after-market hours, pulling back from earlier highs while remaining above its 20-day moving average.

23 sept. 2026, 23:51 UTC

Urban Outfitters Inc. is declining in after-market trading, falling significantly below its 20-day moving average and nearing the lower end of its one-month range.

23 sept. 2026, 23:51 UTC

Guidewire Software Inc's shares are trading modestly higher in after-market hours, continuing a trend of gradual increases since Wednesday's close.

23 sept. 2026, 23:51 UTC

Conagra Brands Inc is seeing modest declines in after-market trading, remaining significantly below its 20-day moving average and near the lower end of its one-month range.

23 sept. 2026, 23:51 UTC

Frontdoor Inc's shares advanced modestly in after-market trading, achieving nearly a 1% cumulative return since Wednesday's close, despite trading near the lower end of its range.

23 sept. 2026, 23:51 UTC

Nu Holdings Ltd. saw a modest increase in after-market trading, recovering from a low point and marking a cumulative return of nearly 1%.

23 sept. 2026, 23:51 UTC

West Pharmaceutical Services Inc is seeing a modest decline in after-market trading, positioned at the lower end of today's range but above its 20-day moving average.

23 sept. 2026, 23:51 UTC

Cable One Inc is trading modestly higher in after-market hours, following a notable peak shortly after the regular session ended.

23 sept. 2026, 23:51 UTC

Vertex Pharmaceuticals Inc saw a modest rise in after-market trading, recovering from a low return shortly after the market closed.

23 sept. 2026, 23:46 UTC

Rocket Pharmaceuticals Inc saw an increase in after-market trading, recovering from an earlier session dip and advancing higher since Wednesday's close.

23 sept. 2026, 23:46 UTC

Boyd Gaming Corp declined in after-market trading, moving from a slight gain to a loss, and is significantly below its 20-day moving average.

23 sept. 2026, 23:46 UTC

Repligen Corp's stock declined in after-market trading, hitting its lowest point of the day after Wednesday's close, despite remaining above its 20-day moving average.

23 sept. 2026, 23:46 UTC

CEVA Inc is trading modestly higher in after-market hours, maintaining strength above its 20-day moving average amid positive private sector activity indicators.

23 sept. 2026, 23:46 UTC

Sirius XM Holdings Inc is down in after-market trading, marking four consecutive sessions of declines and remaining below its 20-day moving average.

Comparaison

Variation de prix

Zentalis Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

185.71% hausse

Prévisions sur 12 Mois

Moyen 8.8 USD  185.71%

Haut 11 USD

Bas 5 USD

Basé sur 6 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

6 ratings

5

Achat

1

Maintien

0

Vente

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.